PT  - JOURNAL ARTICLE
AU  - Christon Grant
AU  - Varun Chalasani
AU  - Jeffrey M Uchin
AU  - Adam Dore
TI  - Atezolizumab-induced scleroderma: a rare complication
AID  - 10.1136/bcr-2021-244968
DP  - 2021 Nov 01
TA  - BMJ Case Reports
PG  - e244968
VI  - 14
IP  - 11
4099  - http://casereports.bmj.com/content/14/11/e244968.short
4100  - http://casereports.bmj.com/content/14/11/e244968.full
SO  - BMJ Case Reports2021 Nov 01; 14
AB  - Few cases of programmed death-ligand 1 inhibitor-induced scleroderma have been reported and their clinical features remain unpublished. Optimal management is, therefore, unknown and an autoantibody association has yet to be identified. We present the case of a female in her 60s who developed skin thickening after starting atezolizumab for metastatic non-small cell lung cancer. Skin biopsy 7 months after symptom onset showed histological changes consistent with scleroderma. Anti-PM/SCL-75 antibody was positive. Atezolizumab was discontinued and treatment was started with mycophenolate mofetil. After 5 months, she experienced mild improvement in skin thickening. Earlier identification of this complication may limit morbidity in this disease process, which otherwise has limited treatment options. In suspected cases, obtaining scleroderma-associated autoantibodies may help with earlier diagnosis.